Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 563 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MRI system Clear all
Recruiting Phase 2 Interventional

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507
View directory record Official record
Conditions
Central Nervous System Cancer, Brain Metastases
Interventions
[C-11]-CS1P1, Brain MRI
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Phase 3 Interventional

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Phase 2 Interventional Results available

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

NCT03641313
View directory record Official record
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy, Irinotecan, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
31
States / cities
Duarte, California • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment

NCT04298242
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
ExAblate 2100
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 30, 2026, 6:11 AM EDT
Completed No phase listed Observational

Escitalopram Neuroimaging Supplement

NCT01398865
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
PET scan and MRI scan
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Early Phase 1 Interventional

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT05291507
View directory record Official record
Conditions
Breast Cancer
Interventions
Muse MRgFUS System
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Physiology of Interregional Connectivity in the Human Brain

NCT03723434
View directory record Official record
Conditions
Healthy, Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions
Single-pulse transcranial magnetic stimulation (spTMS), Paired associative stimulation (PAS), Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging Lung Function Using Oxygen Enhanced MRI

NCT01731015
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions
Medical Grade Oxygen
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Not applicable Interventional Results available

iTBS in Bipolar I Depression

NCT05375214
View directory record Official record
Conditions
Bipolar Depression, Bipolar I Disorder
Interventions
Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 30, 2026, 6:11 AM EDT
Suspended Not applicable Interventional

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

NCT05362032
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy, Endorectal Magnetic Resonance Imaging
Device · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed No phase listed Observational

EURAD MRI Classification of US Indeterminate Adnexa Lesions

NCT02962596
View directory record Official record
Conditions
Ovarian Tumor
Interventions
ADNEXMR SCORING system
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
1,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Emotional and Cognitive Control in Late-Onset Depression

NCT01728194
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Phase 1 Interventional

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Phase 2 Interventional

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting No phase listed Observational

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

NCT07776353
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Electronic health record review, Medical Device Usage and Evaluation, Physical functions assessments, Positron Emission Tomography (PET), Survey Administration
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

NCT00923013
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Cladribine, Rituximab, BMbx, MRI, EKG, Echocardiogram, Abdominal/splenic ultrasound, Stress test
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Not applicable Interventional

Strength Training in Duchenne Muscular Dystrophy

NCT02421523
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Aim 2 Exercise group, Aim 1 Exercise Dosing, Aim 2 Control group
Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 10 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT05278208
View directory record Official record
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
View directory record Official record
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

NCT07776444
View directory record Official record
Conditions
Sickle Cell Disease, Cerebral Stroke
Interventions
Carbon Dioxide
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Image and Model Based Analysis of Lung Disease

NCT03764163
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Pulmonary Function Test, CT Scans, Questionnaires, MRI, Xenon gas
Diagnostic Test · Behavioral · Biological
Lead sponsor
Eric A. Hoffman
Other
Eligibility
20 Years to 89 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 30, 2026, 6:11 AM EDT
Completed Not applicable Interventional Results available

Pilot Study: Safety of a Customized MRI System for Neonatal Imaging

NCT01522339
View directory record Official record
Conditions
Safety of a Customized NICU MRI System
Interventions
GE OPTIMA MR430s with HDX/GE Electronics
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 30, 2026, 6:11 AM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

NCT03233711
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
887
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:11 AM EDT